Vertex Pharmaceuticals INC / Ma

Vertex Pharmaceuticals announced robust second quarter 2026 financial results, with total revenue up 12% to $3.33 billion, and raised its full-year revenue guidance.

Vertex Pharmaceuticals Incorporated held its annual meeting on May 13, 2026, where shareholders voted on key proposals including director elections and stock plan approvals.

Vertex Pharmaceuticals announced an 8% increase in first-quarter 2026 revenue to $2.99 billion, driven by strong performance in cystic fibrosis therapies and growth in new disease areas, while reiterating full-year financial guidance.

Vertex Pharmaceuticals has completed its Biologics Licensing Application submission to the FDA for povetacicept, seeking accelerated approval for immunoglobulin A nephropathy.

Vertex Pharmaceuticals announced robust fourth-quarter and full-year 2025 financial results, driven by CF therapies and new product launches, alongside optimistic 2026 revenue guidance and pipeline advancements.

Vertex Pharmaceuticals reported an 11% increase in Q3 2025 total revenue to $3.08 billion and refined its full-year financial guidance, driven by strong performance in CF therapies and new product launches.

Vertex Pharmaceuticals Inc. announced robust financial results for the first quarter of 2026, driven by strong performance in its cystic fibrosis franchise and diversification into new disease areas.

Vertex Pharmaceuticals reported an 11% increase in net product revenues for the third quarter of 2025, driven by strong demand for TRIKAFTA/KAFTRIO and successful launches of ALYFTREK, CASGEVY, and JOURNAVX.

Vertex Pharmaceuticals reported a significant turnaround in Q2 2025, achieving $1.03 billion in net income driven by strong product revenue growth from TRIKAFTA/KAFTRIO and successful launches of ALYFTREK, CASGEVY, and JOURNAVX.

Vertex Pharmaceuticals reports a 3% increase in total revenue for Q1 2025, driven by TRIKAFTA/KAFTRIO and ALYFTREK, while announcing pipeline advancements and a leadership transition.

Vertex Pharmaceuticals' Q3 2024 results show revenue growth driven by cystic fibrosis treatments, but a net loss for the nine-month period due to a significant acquisition.

Vertex Pharmaceuticals reported a net loss for the second quarter of 2024, primarily due to a significant expense related to the acquisition of Alpine Immune Sciences, despite a revenue increase in their cystic fibrosis (CF) product line.

Vertex Pharmaceuticals reported a 9% increase in total revenues to $12.0 billion in 2025, driven by strong demand for CF medicines and successful launches of CASGEVY and JOURNAVX, while advancing a diversified pipeline.

Vertex Pharmaceuticals' 10-K filing highlights a successful year with increased revenue, new drug approvals, and progress in its diverse pipeline.

Vertex Pharmaceuticals reports a strong 11% increase in net product revenues for 2023, driven by its cystic fibrosis franchise and prepares for potential launches in new therapeutic areas.

Ourania Tatsis, EVP, Chief Reg. & Quality Off. of Vertex Pharmaceuticals Inc / Ma, received 8,251 shares of common stock on July 21, 2026.

Amit Sachdev, EVP Chief Patient & Ext Af Off of Vertex Pharmaceuticals Inc / Ma, received 8,251 shares of common stock on July 21, 2026.

Bruce I Sachs, a Director of Vertex Pharmaceuticals Inc / Ma, received 100 shares of common stock on July 15, 2026.

Alan M Garber, a Director of Vertex Pharmaceuticals Inc / Ma, received 32 shares of common stock on July 15, 2026.

Vertex Pharmaceuticals EVP, Chief Regulatory & Quality Officer, Ourania Tatsis, reported a sale of 1,500 common shares for $524.99 each, executed under a pre-arranged trading plan.

Vertex Pharmaceuticals EVP, Chief Commercial Officer Duncan McKechnie reported a sale of 1,541 shares of common stock on July 2, 2026, executed under a pre-arranged Rule 10b5-1 trading plan.

Vertex Pharmaceuticals' 2026 proxy statement highlights strong 2025 financial performance, pipeline progress, and executive compensation alignment.

Vertex Pharmaceuticals has filed a definitive proxy statement with the SEC.

Vertex Pharmaceuticals achieved significant growth in 2024, driven by commercial success, R&D advancements, and strategic business development, setting the stage for continued value creation.

Vertex Pharmaceuticals Incorporated files a definitive proxy statement with the SEC.

Vertex Pharmaceuticals highlights a transformative year in 2023, marked by growth in cystic fibrosis (CF) treatments, commercial diversification with CASGEVY, and advancements in its pipeline.

Capital Research Global Investors has filed a Schedule 13G, reporting beneficial ownership of 8.3% of Vertex Pharmaceuticals Inc. common stock as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 19,036,076 shares, representing 7.49% of Vertex Pharmaceuticals Inc.'s common stock as of March 31, 2026.

The Vanguard Group, Inc. reports 0% beneficial ownership of Vertex Pharmaceuticals Inc. common stock following an internal realignment.

Capital Research Global Investors has reported a 5.7% passive beneficial ownership stake in Vertex Pharmaceuticals Inc., holding over 14.5 million shares as of March 31, 2025.

Capital World Investors, a division of Capital Research and Management Company, has reported a passive beneficial ownership of 11.2% in Vertex Pharmaceuticals Inc., totaling 28,739,975 shares of common stock as of December 31, 2024.

FMR LLC and its CEO, Abigail P. Johnson, have filed an amended Schedule 13G, reporting a beneficial ownership of 3.6% of Vertex Pharmaceuticals Inc.'s common stock as of December 31, 2024.